You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Althera Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ALTHERA PHARMS, and what generic alternatives to ALTHERA PHARMS drugs are available?

ALTHERA PHARMS has two approved drugs.

There are two US patents protecting ALTHERA PHARMS drugs.

There are seven patent family members on ALTHERA PHARMS drugs in ten countries and fourteen supplementary protection certificates in eight countries.

Summary for Althera Pharms
International Patents:7
US Patents:2
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Althera Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-003 Mar 23, 2021 DISCN Yes No 9,763,885 ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-003 Mar 23, 2021 DISCN Yes No 10,376,470 ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-001 Mar 23, 2021 DISCN Yes No 9,763,885 ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms ROSZET ezetimibe; rosuvastatin calcium TABLET;ORAL 213072-002 Mar 23, 2021 DISCN Yes No 10,376,470 ⤷  Sign Up Y ⤷  Sign Up
Althera Pharms LYPQOZET atorvastatin calcium; ezetimibe TABLET;ORAL 206084-002 Apr 26, 2017 RX No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Althera Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 05C0040 France ⤷  Sign Up PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599 92545 Luxembourg ⤷  Sign Up PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
1003503 05C0048 France ⤷  Sign Up PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
1003503 30/2006 Austria ⤷  Sign Up PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707
0247633 97C0118 France ⤷  Sign Up PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.